Literature DB >> 19111833

Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study.

Mary H Zhang1, Christian Spies, Sadia Ali, Alka M Kanaya, Nelson B Schiller, Mary A Whooley.   

Abstract

OBJECTIVE: Elevated concentrations of adiponectin are associated with a favorable metabolic profile but also with adverse cardiovascular outcomes. This apparent discrepancy has raised questions about whether adiponectin is associated with an increased or decreased risk of coronary heart disease (CHD). We sought to determine whether higher adiponectin levels are associated with exercise-induced ischemia in patients with stable CHD. METHODS AND
RESULTS: We measured total serum adiponectin concentrations and evaluated exercise-induced ischemia by stress echocardiography in a cross-sectional study of 899 outpatients with documented stable CHD. Of these, 217 (24%) had inducible ischemia. Although adiponectin levels correlated negatively with diabetes prevalence, body mass index, serum insulin, fasting glucose, low-density lipoprotein cholesterol, and triglycerides and positively with high-density lipoprotein cholesterol (all P<0.005), elevated adiponectin concentrations were also associated with a greater risk of inducible ischemia. Each standard deviation (0.08 microg/mL) increase in log adiponectin was associated with a 35% greater odds of inducible ischemia (unadjusted odds ratio 1.35; 95% confidence interval 1.15-1.57; P=0.0002). Although attenuated, this association remained present after multivariable adjustment for traditional cardiovascular risk factors and other measures of cardiac function (adjusted odds ratio 1.21; 95% confidence interval 1.02-1.43; P=0.03).
CONCLUSIONS: Elevated concentrations of adiponectin are independently associated with inducible ischemia in patients with stable CHD. These findings raise the possibility that the presence of chronic inducible ischemia may alter the cardio-protective effects afforded by adiponectin secretion in the healthy population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111833      PMCID: PMC2779844          DOI: 10.1016/j.atherosclerosis.2008.11.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

1.  Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000.

Authors:  W Rathmann; B Haastert; C Herder; H Hauner; W Koenig; C Meisinger; R Holle; G Giani
Journal:  Int J Obes (Lond)       Date:  2006-11-21       Impact factor: 5.095

2.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Giovanni Tripepi; Francesco A Benedetto; Sebastiano Cutrupi; Saverio Parlongo; Lorenzo S Malatino; Graziella Bonanno; Giuseppe Seminara; Francesco Rapisarda; Pasquale Fatuzzo; Michele Buemi; Giacomo Nicocia; Sachiyo Tanaka; Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

3.  High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease.

Authors:  Serdar Soydinc; Vedat Davutoglu; Ibrahim Sari
Journal:  Tohoku J Exp Med       Date:  2007-04       Impact factor: 1.848

4.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.

Authors:  N Ouchi; S Kihara; Y Arita; K Maeda; H Kuriyama; Y Okamoto; K Hotta; M Nishida; M Takahashi; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  1999 Dec 21-28       Impact factor: 29.690

5.  Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study.

Authors:  Anil K Gehi; Sadia Ali; Beeya Na; Nelson B Schiller; Mary A Whooley
Journal:  Arch Intern Med       Date:  2008-07-14

6.  High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men.

Authors:  Maximilian von Eynatten; Per M Humpert; Annabelle Bluemm; Philipp M Lepper; Andreas Hamann; Bruno Allolio; Peter P Nawroth; Angelika Bierhaus; Klaus A Dugi
Journal:  Atherosclerosis       Date:  2007-11-19       Impact factor: 5.162

7.  Prognostic value of adiponectin for cardiovascular disease and mortality.

Authors:  Jacqueline M Dekker; Tohru Funahashi; Giel Nijpels; Stefan Pilz; Coen D A Stehouwer; Marieke B Snijder; Lex M Bouter; Yuji Matsuzawa; Iichiro Shimomura; Robert J Heine
Journal:  J Clin Endocrinol Metab       Date:  2008-01-22       Impact factor: 5.958

8.  Adiponectin reduces lipid accumulation in macrophage foam cells.

Authors:  Ling Tian; Nanlan Luo; Richard L Klein; B Hong Chung; W Timothy Garvey; Yuchang Fu
Journal:  Atherosclerosis       Date:  2008-04-20       Impact factor: 5.162

9.  High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study.

Authors:  Naveed Sattar; Pauline Watt; Lynne Cherry; Shah Ebrahim; George Davey Smith; Debbie A Lawlor
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

10.  Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study.

Authors:  Birgit-Christiane Zyriax; Petra Algenstaedt; Utz Florian Hess; Mark Schöffauer; Christoph Bamberger; Heiner Boeing; Eberhard Windler
Journal:  Atherosclerosis       Date:  2008-02-08       Impact factor: 5.162

View more
  2 in total

Review 1.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

2.  Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study.

Authors:  Alexis L Beatty; Mary H Zhang; Ivy A Ku; Beeya Na; Nelson B Schiller; Mary A Whooley
Journal:  Atherosclerosis       Date:  2011-12-07       Impact factor: 5.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.